摘要
目的:探讨孟鲁司特防治过敏性紫癜肾损害的临床有效性和安全性。方法:采用随机对照方法,将200例过敏性紫癜患儿分为实验组(100例)和对照组(100例),两组患儿均给予常规治疗,实验组采用孟鲁司特进行治疗,对照组采用低分子肝素钙进行治疗,观察两组临床治疗效果及不同时间段微量白蛋白、尿β2微球蛋白变化。结果:实验组有效率为91.00%,明显高于对照组的81.00%(χ2=4.15,P<0.05)。实验组儿童皮疹消失时间、腹痛和关节疼痛缓解时间以及总病程均明显短于对照组(P<0.01)。治疗后实验组尿微量白蛋白、尿β2微球蛋白水平明显低于对照组(P<0.01)。结论:孟鲁司特预防过敏性紫癜肾损害方法简单,安全可靠,值得临床推广应用。
ABSTRACT AIM. To observe the clinical effi- cacy and safety of montelukast in prevention of Henoch-Schonlein purpura with renal impair- ment. METHODS： Using a randomized con- trolled method, 200 cases of Henoch-Schonlein syndrome were randomly divided into the experi- mental group （n = 100） and control group （n = 100） ,two groups were given conventional treat- ment, the experimental group was based on com- bined with montelukast and the control group was based on combined with low molecular hepa- rin sodium. The clinical treatment result, the changes of urine albumin and β2 mieroglobulin levels in different time periods were observed. RESULTS： Efficacy of the experimental group was 91. 00% while the control group was81.00% （X2 =4.15, P〈0.05） . Compared with the control group,the children disappearing time rash, abdominal pain and joint pain remission time and the total duration in the experimental group were significantly shorter （P〈0.01）. Af- ter treatment, the levels of urinary albumin and urinary β2 microglobulin in experimental group were significantly lower than those in the control group （P〈0. 01）. CONCLUSION： The preven- tive effect of montelukast on henoch-schonlein purpura with renal involvement method is sim- ple, safe, so it deserves preference in clinic.
出处
《中国临床药理学与治疗学》
CAS
CSCD
2014年第7期805-808,共4页
Chinese Journal of Clinical Pharmacology and Therapeutics
关键词
孟鲁司特
过敏性紫癜
过敏性紫癜肾炎
montelukast
henoch-schonleinpurpura
henoch-schonlein purpura nephritis
